LakePharma, a biologics contract research development and manufacturing organization (CRDMO), and NJ Biopharmaceuticals, a contract research organization (CRO) providing integrated chemistry and biology services, have formed an alliance to offer streamlined antibody-drug conjugate (ADC) development solutions for the biotechnology and pharmaceutical sectors.
 
LakePharma has been a supplier of novel antibodies for over 10 years, and NJ Bio has expertise in linker-payload synthesis and bioconjugation to create ADCs. LakePharma will manufacture and provide antibodies as starting materials for ADC development carried out by NJ Bio in a single, seamless workflow for clients, making therapeutic ADC manufacturing from initial antibody discovery to the production of the drug conjugates significantly more efficient both in time and expense.
 
“LakePharma is an expert in antibody discovery, engineering, and production while NJ Bio is a pioneer in performing chemistries with antibodies,” said Hua Tu, chief executive officer, LakePharma. “An alliance between these two companies makes perfect sense. Our partnership with NJ Bio allows us to provide a one-stop experience for our contract research partners.”
 
Nareshkumar Jain, president and chief executive officer, NJ Bio, said, “This alliance will expand and add value to the ADC services we currently provide to our clients, creating cost-effective solutions through the provision of complementary service offerings between NJ Bio and LakePharma.”